• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
OPT 2.40% 64.0¢

OPTHEA LIMITED - Corporate Spotlight

Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the... Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No Corporate Spotlight currently available.

(20min delay)
Last
64.0¢
Change
0.015(2.40%)
Mkt cap ! $424.1M
Open High Low Value Volume
64.5¢ 67.0¢ 64.0¢ $138.1K 211.7K

Buyers (Bids)

No. Vol. Price($)
1 4904 64.0¢
 

Sellers (Offers)

Price($) Vol. No.
65.0¢ 43573 1
View Market Depth
Last trade - 16.10pm 29/04/2024 (20 minute delay) ?
Last
64.0¢
  Change
0.015 ( 2.84 %)
Open High Low Volume
65.0¢ 66.5¢ 64.0¢ 39023
Last updated 15.59pm 29/04/2024 ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.